Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Philippe Moreau, Saad Zafar Usmani, Niels W.C.J. van de Donk, Alfred L. Garfall, Michel Delforge, Albert Oriol Rocafiguera, Ajay K. Nooka, Laura Rosiñol, Nizar J. Bahlis, Paula Rodríguez-Otero, Thomas G. Martin, Joris Diels, Suzy Van Sanden, Lixia Pei, Eric Ammann, Rachel Kobos, Mary Slavcev, Jennifer Smit, Anil Londhe, Amrita Y. Krishnan
Institutions: Memorial Sloan Kettering Cancer Center, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Abramson Cancer Center, University of Pennsylvania, KU Leuven, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Winship Cancer Institute, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, University of Calgary, Clinica Universidad de Navarra, University of California, San Francisco, Janssen (Belgium), Janssen Research & Development (United States), City Of Hope National Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286298030